Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home
Patient Information

Our Investigators

Chairman's Office

Carla Greenbaum, M.D., Type 1 Diabetes TrialNet Principal Investigator and Vice Chair, Benaroya Research Institute
Leader in clinical investigations and trials to prevent or intervene with the diabetes autoimmune process and well-known as an expert in designing research protocols for children with diabetes.

Lisa E. Rafkin, MS, RD, CDE, Type 1 Diabetes TrialNet, University of Miami
Coordinates study-wide operations between the University of Miami's Diabetes Research Institute, NIH, and the Type 1 Diabetes TrialNet Coordinating Center.

NIDDK

Ellen Leschek, M.D., Type 1 Diabetes TrialNet Program Director, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Pediatric endocrinologist, clinical researcher, and clinical research director who provides scientific and managerial oversight to Type 1 Diabetes TrialNet and its multi-center studies.

Lisa Spain, Ph.D. Program Director for Autoimmune Endocrine Diseases, Division of Diabetes, Endocrinology & Metabolism, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Molecular and Cellular Immunologist, provides scientific and managerial oversight for mechanistic and laboratory activities within Type 1 Diabetes TrialNet and its multi-center studies.

Australia

John M. Wentworth, M.D., Type 1 Diabetes Principal Investigator, Walter and Eliza Hall Research Institute. Responsible for the Natural History Study and Oral Insulin Study in subjects at risk for new onset type 1 diabetes. Heads the network of TrialNet clinical sites in Australia.

California

Stephen E. Gitelman, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of California San Francisco Children's Hospital
Pediatric endocrinologist and diabetes researcher who is working with scientists around the world to create new treatments to block autoimmune destruction of insulin-producing beta cells, improve current treatments, and ultimately prevent the disease.

Darrell Wilson, M.D., Type 1 Diabetes TrialNet Principal Investigator, Stanford University
Expansive career in pediatric endocrinology and diabetes includes current position as the Chief of Pediatric Endocrinology and Diabetes at the Lucile Packard Children's Hospital at Stanford.

Colorado

Peter Gottlieb, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Colorado at Denver

Connecticut

Kevan C. Herold, M.D., Type 1 Diabetes TrialNet Principal Investigator, Yale University School of Medicine
Well known in the field of type 1 diabetes research for being part of the team that was the first to report use of anti-CD3 monoclonal antibody, a treatment now in development.

Finland

Mikael Knip, M.D., Ph.D., Type 1 Diabetes TrialNet Principal Investigator, University of Helsinki.

Florida

Jennifer B. Marks, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Miami, Miller School of Medicine
Endocrinologist/diabetologist who sees patients, teaches, and conducts clinical research in several areas of diabetes, including prevention, treatment, and prevention of complications.

Henry Rodriguez, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of South Florida.

Desmond Schatz. M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Florida College of Medicine
Well-known and published pediatric endocrinologist involved in type 1 diabetes research with a focus on the prediction, natural history, genetics, immunopatho-genesis and prevention of type 1 diabetes, as well as the management of type 1 diabetes in children and adolescents.

Georgia

Andrew Muir, M.D., Type 1 Diabetes TrialNet Principal Investigator, Emory University.

Germany

Anette-Gabrielle Ziegler, M.D., Type 1 Diabetes TrialNet Principal Investigator, Forschergruppe Diabetes.

Indiana

Linda A. DiMeglio, MD, MPH, Type 1 Diabetes TrialNet Principal Investigator, Indiana University School of Medicine
Associate Professor of Pediatrics, Department of Pediatrics, Section of Pediatric Endocrinology/Diabetology, Riley Hospital for Children, Indiana University School of Medicine

Italy

Emanuele Bosi, M.D., Type 1 Diabetes Principal Investigator, San Raffaele Hospital

Responsible for the Natural History Study and Oral Insulin Study in subjects at risk for new onset type 1 diabetes. Heads the network of TrialNet clinical sites in Italy and Germany.

Minnesota

Antoinette Moran, M.D., Type 1 Diabetes TrialNet Regional Principal Investigator, University of Minnesota
Highly published author on diabetes complications, who specializes in clinical trials to prevent or delay the onset of type 1 diabetes; co-directs the assessment of metabolic endpoints to improve the efficacy of islet transplantation of type 1 diabetes.

Missouri

Wayne Moore, M.D., Ph.D, Type 1 Diabetes TrialNet Co-Principal Investigator, Children’s Mercy Hospital.

Mark Clements, M.D., Type 1 Diabetes TrialNet Co-Principal Investigator, Children’s Mercy Hospital.

New York

Robin Goland, M.D., Type 1 Diabetes TrialNet Principal Investigator, Columbia University
Noted clinical investigator who is part of the team who established the Naomi Berrie Diabetes Center and has guided it to a premier, family-focused diabetes care and research facility.

Ontario, Canada

Diane Wherrett, MD, FRCPC, Type 1 Diabetes Principal Investigator. Chair of GAD New Onset Trial, Vice-Chair GAD Prevention Trial, Chair of Eligibility Committee, Vice-Chair of Ancillary Studies Committee.

Endocrinologist and Associate Professor in the Department of Pediatrics for The Hospital for Sick Children, University of Toronto. Heads the Canadian network of TrialNet clinical sites.

Pennsylvania

Dorothy J. Becker, MBBCh, Type 1 Diabetes TrialNet Principal Investigator and Regional Coordinator, Children's Hospital of Pittsburgh
International speaker and recognized expert in the treatment and prevention of diabetes in children.

Sweden

Åke Lernmark, MD, Ph.D., Type 1 Diabetes TrialNet Principal Investigator, Professor in Experimental Diabetes, Lund University/CRC, Malmö, Sweden. His research is focused on studies on autoimmune triggers in the TEDDY study, prediction of diabetes and celiac disease in the Diabetes Prediction in Skåne (DiPiS) study and prevention of type 1 diabetes by immune tolerance in TrialNet.

Tennessee

William E. Russell, M.D., Type 1 Diabetes TrialNet Principal Investigator, Vanderbilt Eskind Diabetes Clinic.

Texas

Philip Raskin, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Texas Southwestern Medical Center
Clinical researcher widely renowned for his work in diabetes, diabetes complications, and diabetes management.

Maria Redondo, M.D., Ph.D., MPH, Type 1 Diabetes TrialNet Principal Investigator, Baylor College of Medicine.

United Kingdom

Penelope Bingley, M.D., Type 1 Diabetes Principal Investigator, University of Bristol. Member of TN01 Natural History Study Chair Committee and Chair of Dried-Blood Spot Ancillary Study Committee. Professor of Diabetic Medicine at the University of Bristol and Honorary Consultant Physician at Southmead Hospital and Bristol Royal Infirmary, Bristol. Heads the network of TrialNet clinical sites in the United Kingdom.

Washington

Carla Greenbaum, M.D., Type 1 Diabetes TrialNet Principal Investigator and Vice Chair, Benaroya Research Institute
Leader in clinical investigations and trials to prevent or intervene with the diabetes autoimmune process and well-known as an expert in designing research protocols for children with diabetes.

Back To Top